MDT-AP-2036
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 6
- sex
- F
- new_clusters
- C2
- umap1_2d
- 2.648287889
- umap2_2d
- 2.154278744
- umap1_3d
- 0.002836693
- umap2_3d
- -1.999804587
- umap3_3d
- -2.438886288
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.510
- IL6_JAK_STAT3_SIGNALING+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- INTERFERON_GAMMA_RESPONSE+0.490
- MYC_TARGETS_V2+0.480
- MYC_TARGETS_V1+0.470
- INFLAMMATORY_RESPONSE+0.460
- INTERFERON_ALPHA_RESPONSE+0.450
- P53_PATHWAY+0.400
- E2F_TARGETS+0.390
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.290
- BILE_ACID_METABOLISM-0.150
- KRAS_SIGNALING_DN-0.150
- UV_RESPONSE_DN-0.150
- SPERMATOGENESIS-0.120
- NOTCH_SIGNALING-0.090
- MITOTIC_SPINDLE-0.070
- PANCREAS_BETA_CELLS-0.040
- PEROXISOME-0.030
- HEME_METABOLISM+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.919 |
| 2 | D06FFD0C-80D4-413D-9C83-62D9C163EDAB | — | — | 0.913 |
| 3 | SRR934883 | — | — | 0.911 |
| 4 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.910 |
| 5 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.908 |
| 6 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.908 |
| 7 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.907 |
| 8 | 53B31ABD-AD68-4A44-A525-23FD413115D5 | — | — | 0.906 |
| 9 | 5307FA7F-DFE5-42BC-BFC7-826AACAAE799 | — | — | 0.906 |
| 10 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| APOPTOSIS | 0.340 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |